|
Ki-67 Biomarker Expression and Its Relationship with Metastasis Time and Location in Breast Cancer Patients
|
Abdolreza Fazel1    , Seyed Reza Khandoozi *2 , Gholamreza Roshandel3 , Ashour Kor4 |
1- Associate Professor of Surgery, Cancer Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran.
2- Assistant Professor, Cancer Research Center, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. , dr.khandoozi@goums.ac.ir
3- Associate Professor, Golestan Research Center of Gastroenterology and Hepatology, Jorjani Clinical Sciences Research Institute, Golestan University of Medical Sciences, Gorgan, Iran.
4- General Physician, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran. |
|
|
Abstract: (431 Views) |
Background and Objective: Breast cancer is the most common cancer among women, causing the death of many worldwide each year. Given the importance of determining prognosis and the role of biomarkers, this study aimed to determine the expression level Ki-67 biomarker and its relationship with metastasis time and location in breast cancer patients.
Methods: This descriptive-analytical study was conducted on 154 breast cancer women admitted to the Fifth Azar Educational-Therapeutic Center in Gorgan, Iran, during 2009-2019. Upon admission, Ki-67 expression levels in tissue were determined using immunohistochemistry (IHC). Other required information, including demographic characteristics, disease stage, time interval from diagnosis to metastasis, and metastasis location, were identified and evaluated.
Results: Most of the patients (63%) were in the 40-60 age group. Ki-67 levels were determined to be below 15% in 45 patients (29.2%) and above 15% in 109 patients (70.8%). A statistically significant relationship was observed between Ki-67 expression levels and the time interval from diagnosis to metastasis (P<0.05). No statistically significant relationship was found between Ki-67 expression levels and age group, metastasis location, or disease stage.
Conclusion: The results of this study demonstrated that individuals with tissue Ki-67 levels above 15% experienced metastasis within a shorter period of time.
|
|
Keywords: Breast Neoplasms [MeSH], Biomarkers [MeSH], Ki-67 Antigen [MeSH]
Article ID: Vol27-24 |
|
|
Full-Text [PDF 544 kb]
(174 Downloads)
| | Abstract (HTML) (6 Views)
|
|
Type of Study: Original Articles |
Subject:
Oncology
|
|
|
|
|
|
|
| References |
1. Kazemi M, Amani J, Salmanian AH, Forghanifard MM, Aghamollaei H. [Design and Expression of Recombinant HER-2 Antigen as a Marker for Detection of Breast Cancer]. Modares Journal of Medical Sciences: Pathobiology. 2015;17(4):88-99. [Article in Persian] [ Link] 2. Dvir K, Giordano S, Leone JP. Immunotherapy in Breast Cancer. Int J Mol Sci. 2024 Jul; 25(14): 7517. https://doi.org/10.3390/ijms25147517. [ DOI] [ PubMed] 3. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42. https://doi.org/10.3322/caac.21320. [ DOI] [ PubMed] 4. Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-95. https://doi.org/10.3322/caac.21863. [ DOI] [ PubMed] 5. Valizadeh Otaghsara SM, Ghorbanzadeh V, Esmaeil Lashgarian H, Hashemzadeh P, Dariushnejad H. Molecular insight in breast cancer metastasis. Yafte. 2020;22(2):71-88. [Article in Persian] [ Link] 6. Golmohammadi R, Pejhan A. [Gene experison of cell proliferative marker Ki67 in breast cancer]. J Gorgan Univ Med Sci. 2011;13(3):65-71. [Article in Persian] [ Link] 7. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma. 2018 Jun;127(2):175-86. https://doi.org/10.1007/s00412-018-0659-8. [ DOI] [ PubMed] 8. Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. Cell Death Differ. 2021 Dec;28(12):3357-70. https://doi.org/10.1038/s41418-021-00823-x. [ DOI] [ PubMed] 9. Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013 Jun;139(2):539-52. https://doi.org/10.1007/s10549-013-2560-8. [ DOI] [ PubMed] 10. Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016 Dec;13(4):496-504. https://doi.org/10.20892/j.issn.2095-3941.2016.0066. [ DOI] [ PubMed] 11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011 Aug;22(8):1736-47. https://doi.org/10.1093/annonc/mdr304. [ DOI] [ PubMed] 12. Woo JW, Chung YR, Ahn S, Kang E, Kim EK, Kim SH, et al. Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. J Breast Cancer. 2019 Sep;22(3):439-52. https://doi.org/10.4048/jbc.2019.22.e38. [ DOI] [ PubMed] 13. Ragab HM, Samy N, Afify M, El Maksoud NA, Shaaban HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J Genet Eng Biotechnol. 2018 Dec;16(2):479-84. https://doi.org/10.1016/j.jgeb.2018.03.002. [ DOI] [ PubMed] 14. Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011 Oct;9:131. https://doi.org/10.1186/1477-7819-9-131. [ DOI] [ PubMed] 15. Abdollahiyan Somesaraei T, Heidarpour P. [Prevalence of risk factors for breast cancer in 30-59 year-old women in comprehensive rural health services in Somesara country in 2018]. Nursing and Midwifery Journal. 2020; 17(12):965-74. [Article in Persian] [ Link] 16. Naghi Pour A, Moghimbeigi A, Shirmohamadi N, Soltanian A, Khazaei S, Nick Ceiar S. [Geographical Distribution of Breast Cancer in Hamadan Province during 2008-2015 Using Bayesian Method]. IJE. 2022; 17(4):362-71. [Article in Persian] [ Link] 17. Erić I, Petek Erić A, Kristek J, Koprivčić I, Babić M. Breast cancer in young women: Pathological and Immunohistochemical features. Acta Clin Croat. 2018 Sep;57(3):497-502. https://doi.org/10.20471/acc.2018.57.03.13. [ DOI] [ PubMed] |
|
| Send email to the article author |
|
|
|
Fazel A, Khandoozi S R, Roshandel G, Kor A. Ki-67 Biomarker Expression and Its Relationship with Metastasis Time and Location in Breast Cancer Patients. J Gorgan Univ Med Sci 2025; 27 (3) :32-38 URL: http://goums.ac.ir/journal/article-1-4478-en.html
|
